Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...

Dark Blue Therapeutics ("Dark Blue"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen (NASDAQ: AMGN).

In what is thought to be the first major pharma M&A deal of the year, Amgen has bought Oxford, UK-based biotech Dark Blue ...

California healthcare innovator Amgen, which already has facilities at Cambridge Science Park, has made a new and incisive acquisition in the UK - buying Oxford University spin-out Dark Blue ...